Chemotherapy-induced cardiomyopathy

被引：9

作者：

Yusuf, Syed Wamique ^{[1
]}

Ilias-Khan, Nasreen A. ^{[1
]}

Durand, Jean-Bernard ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, 1515 Holcombe Blvd,Unit 1451, Houston, TX 77030 USA

来源：

EXPERT REVIEW OF CARDIOVASCULAR THERAPY | 2011年 / 9卷 / 02期

关键词：

cancer; cardiomyopathy; chemotherapy;

D O I：

10.1586/ERC.10.188

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Improvement in cancer therapy has led to an increasing number of cancer survivors, some of whom may suffer from the cardiotoxic effects of chemotherapy. Cardiomyopathy can occur years after completion of the chemotherapy and it is important to recognize this early, as complete recovery of cardiac function is possible in some cases. In this article we will review chemotherapy-induced cardiomyopathy and discuss its treatment options.

引用

页码：231 / 243

页数：13

共 136 条

[1]

ALI MK, 1994, CANCER-AM CANCER SOC, V74, P182, DOI 10.1002/1097-0142(19940701)74:1<182::AID-CNCR2820740129>3.0.CO

[2]

2-2

[3] L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes:: role of inhibition of ceramide generation [J].